Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271099 | 1.00 | DDB1 (0.48) | DDB1CRBNMAOAMAOBPOLB | |
| SCHEMBL15271043 | 0.98 | DDB1 (0.49) | DDB1CRBNMAOAMAOBPOLB | |
| SCHEMBL15271026 | 0.94 | DDB1 (0.49) | DDB1CRBNMAOAMAOBPOLB | |
| SCHEMBL15271053 | 0.90 | DDB1 (0.51) | DDB1CRBNMAOAMAOBPOLB | |
| SCHEMBL19890876 | 0.86 | MAOA (0.55) | DDB1CRBNMAOAMAOBPOLB | |
| SCHEMBL18376190 | 0.82 | DDB1 (0.46) | DDB1CRBNMAOAMAOBPOLB | |
| SCHEMBL18376187 | 0.82 | HTR2C (0.53) | DDB1CRBNPOLBKMT2AACHE | |
| SCHEMBL25107075 | 0.82 | DDB1 (0.43) | DDB1CRBNMAOAMAOBPOLB | |
| Hydrochloric Acid SCHEMBL23799249 | 0.81 | HTR2C (0.54) | DDB1CRBNPOLBKMT2A | |
| Hydrochloric Acid SCHEMBL30832113 | 0.81 | HTR2C (0.54) | DDB1CRBNPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3592729-B1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-06-30 | — | — | EP | disclosed |
| EP-3592729-B1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-20210130286-A1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130286-A1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2021-05-06 | — | — | US | disclosed |
| US-9650456-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-2825574-B1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORP (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150031845-A1 | Process For Producing Polydienes | BRIDGESTONE CORPORATION (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2825574-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013138270-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTSONE CORPORATION (JP) | 2013-09-19 | — | — | WO | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064869-A2 | CATALYSTS FOR ARYL SULFIDE SYNTHESIS AND METHOD OF PRODUCING ARYL SULFIDES | YALE UNIVERSITY (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130286-A1 | CATALYTIC C-X-BOND METATHESIS THROUGH ARYLATION | AOX1, TYR, CXXC4 | DDB1 1738/4885CRBN 233/4885MAOA 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.